Nachrichten zur Illumina Inc. Aktie

Aktienmarkt: Aktie von Illumina tritt auf der Stelle (102,0607 €)

Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Illumina . Das Papier notiert gegenwärtig bei 109,80 US-Dollar. Kaum verändert im…

Illumina: Dauerhafte Wachstumsstorys sollten belohnt werden - Aktienanalyse

New York (www.aktiencheck.de) - Illumina-Aktienanalyse von Jefferies & Co: Die Analysten von Jefferies & Co nehmen die Coverage der Aktie von…

Illumina board approves spinoff of GRAIL

…

Illumina to spin off Grail in June

Illumina , a maker of gene sequencing machines, said on Monday it expected to spin off cancer test maker Grail…

Illumina to spin off Grail in June By Reuters

Illumina to spin off Grail in June…

Illumina, Inc. (ILMN) Bernstein Strategic Decisions Conference (Transcript)

…

Aktie von Illumina an der Börse auf der Verliererseite: Börsenkurs fällt deutlich (94,1776 €)

An der US-amerikanischen Börse fällt zur Stunde die Illumina-Aktie negativ auf. Das Papier verbilligt sich am Mittwoch deutlich. Zu den…

Global Precision Oncology Market Size To Exceed USA 260.5 Billion By 2033 | CAGR Of 10.21%

The Global Precision Oncology Market Size was Valued at USD 98.5 Billion in 2023 and the Worldwide Precision Oncology Market…

The Zacks Analyst Blog Highlights Union Pacific, Freeport-McMoRan, Block, Xcel and Illumina

Union Pacific, Freeport-McMoRan, Block, Xcel and Illumina are included in this Analyst Blog.…

Illumina, Inc. (ILMN) RBC Capital Markets Global Healthcare (Transcript)

…

Illumina shares gain 4% on upbeat RBC comments By Investing.com

Illumina shares gain 4% on upbeat RBC comments…

Illumina: Kursziel gesenkt

Toronto (www.aktiencheck.de) - Rating-Update: Die Analysten der Scotiabank stufen die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol: ILU, NASDAQ-Symbol:…

Illumina, Inc. (ILMN) Q1 2024 Earnings Call Transcript

…

Illumina reaffirms annual revenue forecast over continued sluggish demand By Reuters

Illumina reaffirms annual revenue forecast over continued sluggish demand…

Illumina earnings beat by $0.05, revenue topped estimates By Investing.com

Illumina earnings beat by $0.05, revenue topped estimates…

Aktie von Illumina heute am Aktienmarkt gefragt (116,9609 €)

Im Plus liegt zur Stunde die Illumina-Aktie . Zuletzt zahlten Investoren für das Wertpapier 125,34 US-Dollar. Ein Wertanstieg von 2,50…

Genomics Luminary and former Illumina Executive Bob Kain Joins Single Technologies as an Advisor

Stockholm, Sweden, 23 April 2024 – Renowned genomics pioneer, Bob Kain, has joined Single Technologies as an advisor to support…

Illumina: EU-Genehmigung des Verkaufsplans für Grail - Aktienanalyse

New York (www.aktiencheck.de) - Illumina-Aktienanalyse von Evercore ISI: Vijay Kumar, Analyst von Evercore ISI, nimmt in einer aktuellen Aktienanalyse die Aktie…

Kurs fällt um 3,75 Prozent: Illumina-Aktie unter Druck (115,0253 €)

An der US-amerikanischen Börse fällt gegenwärtig die Illumina-Aktie negativ auf. Das Papier verliert deutlich an Wert. Mit einem Kurssturz von…

Global Theranostics Market Size To Worth USD 3.3 Billion By 2033 | CAGR of 5.68%

The Global Theranostics Market Size was Valued at USD 1.9 Billion in 2023 and the Worldwide Theranostics Market Size is…

EU approves Illuminas plan to divest cancer test maker Grail By Reuters

EU approves Illuminas plan to divest cancer test maker Grail…

illumin Holdings Inc. announces date for First Quarter 2024 Financial and Operating Results

TORONTO, April 11, 2024 (GLOBE NEWSWIRE) -- illumin Holdings Inc. (TSX: ILLM) (“illumin” or “Company”), a journey advertising…

Illumina CFO steps down amid executive shakeup

…

Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed

Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by…

Illumina CFO Goswami to depart, Summit Therapeutics Dhingra named successor By Reuters

Illumina CFO Goswami to depart, Summit Therapeutics Dhingra named successor…

Illumina: Downgrade

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von OTR Global stufen die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol:…

EU court should back Illuminas appeal against EU review of Grail deal, court adviser says By Reuters

EU court should back Illuminas appeal against EU review of Grail deal, court adviser says…

Illumina shares fall as Ichan reportedly abandons second proxy contest By Investing.com

Illumina shares fall as Ichan reportedly abandons second proxy contest…

Exclusive-Icahn drops Illumina board challenge threat, sources say

Activist investor Carl Icahn has dropped a threat to mount a new challenge to Illuminas board, sparing the U.S. gene…

Exclusive-Icahn drops Illumina board challenge threat, sources say By Reuters

Exclusive-Icahn drops Illumina board challenge threat, sources say…

Illuminas Turnaround Play: Betting On NovaSeq X Amidst Rising Competitive Tides

…

ILLUMINA ALERT: Bragar Eagel & Squire, P.C. is Investigating Illumina, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Kursgewinne für den Anteilsschein von Illumina (126,1800 €)

Am US-amerikanischen Aktienmarkt notiert die Illumina-Aktie zur Stunde fester. Zuletzt zahlten Investoren für die Aktie 136,87 US-Dollar. Der Anteilsschein von…

4 Overvalued Stocks Ripe for a Short as Market Scrambles for Direction After ATHs

Stocks Analysis by Investing.com (Ismael De La Cruz) covering: S&P 500, Illumina Inc, DexCom Inc, Insulet Corporation. Read Investing.com (Ismael…

Illumina (ILMN) Rides on NGS Portfolio Expansion Amid Macro Woe

In reproductive health, Illumina (ILMN) primarily focuses on driving noninvasive prenatal testing (NIPT) adoption globally.…

Illumina, Inc. (ILMN) Q4 2023 Earnings Call Transcript

…

Illumina forecasts flat 2024 sales as sluggish demand drags on By Reuters

Illumina forecasts flat 2024 sales as sluggish demand drags on…

Global Nucleic Acid Sample Preparation Kit Market Size To Worth USD 11,200.5 Million By 2033 | CAGR of 10.27%

The Global Nucleic Acid Sample Preparation Kit Market Size was valued at USD 4,213.0 Million in 2023 and the Worldwide…

Analyst Report: Illumina Inc

…

Prenatal DNA Sequencing: Global Market Analysis Through 2018-2033 by Type, Application, End User and Region

Dublin, Jan. 19, 2024 (GLOBE NEWSWIRE) -- The "Prenatal DNA Sequencing Global Market Report 2024" report has been…

Concentric by Ginkgo and Illumina join hands for pathogen monitoring programs

…

Illumina (ILMN) Shares Down 1.2% Post Preliminary Q4 Results

Illuminas (ILMN) fourth-quarter 2023 results are likely to reflect the impacts of the adoption of its new generation of distributed…

Illumina, Inc. (ILMN) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

…

Illumina unveils preliminary fourth-quarter revenue that tops estimates By Investing.com

Illumina unveils preliminary fourth-quarter revenue that tops estimates…

Illumina: Abstufung

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von TD Cowen stufen die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol:…

ILLUMINA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Illumina, Inc. and Encourages Investors to Contact the Firm

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

ILMN FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Illumina, Inc. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action – ILMN

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Illumina, Inc. (ILMN)

LOS ANGELES, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of…

ILLUMINA SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Illumina To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $100,000 investing in Illumina securities between September 21, 2020 and November 9, 2023 and would…

Pfizer and Illumina downgraded but Merck can deliver, declares TD Cowen By Investing.com

Pfizer and Illumina downgraded but Merck can deliver, declares TD Cowen…